Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Invent Medic Sweden AB's Debt-to-Equity or its related term are showing as below:
XSAT:IMS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.15 Med: 0.4 Max: 1
Current: 0.16
During the past 10 years, the highest Debt-to-Equity Ratio of Invent Medic Sweden AB was 1.00. The lowest was 0.15. And the median was 0.40.
XSAT:IMS's Debt-to-Equity is ranked better than 59.94% of 699
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs XSAT:IMS: 0.16
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Invent Medic Sweden AB Debt-to-Equity Related Terms
Invent Medic Sweden AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Invent Medic Sweden AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:IMS vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Invent Medic Sweden AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invent Medic Sweden AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Invent Medic Sweden AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Invent Medic Sweden AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invent Medic Sweden AB (XSAT:IMS) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Invent Medic Sweden AB and its competitors. Over the past decade, Invent Medic Sweden AB's Debt-to-Equity has ranged from 0.15 to 1.00. According to the industry distribution chart, Invent Medic Sweden AB ranks #280 out of 699 companies in the Medical Devices & Instruments industry, placing it in the top 40.1%.
Is Invent Medic Sweden AB's Debt-to-Equity too high?
Invent Medic Sweden AB's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 1.00. Based on the distribution chart, Invent Medic Sweden AB ranks #280 out of 699 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Invent Medic Sweden AB has a GF Score™ of 32/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Invent Medic Sweden AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Invent Medic Sweden AB ranks #280 out of 699 companies for Debt-to-Equity. This puts Invent Medic Sweden AB in the upper half of its industry. The industry median Debt-to-Equity is 0.24. Historically, Invent Medic Sweden AB's own Debt-to-Equity has ranged from 0.15 to 1.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Invent Medic Sweden AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invent Medic Sweden AB's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invent Medic Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Invent Medic Sweden AB (XSAT:IMS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.13, compared to a current price of kr0.12 — trading 10% below its estimated fair value. The current Debt-to-Equity is 0.00. Invent Medic Sweden AB's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Invent Medic Sweden AB (XSAT:IMS), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Invent Medic Sweden AB (XSAT:IMS) Overvalued in 2026?
Based on GuruFocus' analysis, Invent Medic Sweden AB stock appears to be undervalued.
The current stock price of kr0.12 is trading 10% below its estimated GF Value™ of kr0.13.
GuruFocus considers Invent Medic Sweden AB to be Modestly Undervalued.
Key valuation signals for XSAT:IMS:
Debt-to-Equity: 0.00
GF Value™: kr0.13 vs. price of kr0.12 (10% below fair value)
No single metric tells the full story. See the XSAT:IMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Invent Medic Sweden AB develops and markets its product - Efemia bladder support, a vaginal medical device for the treatment of female urinary incontinence.
32GF Score
Get the complete analysis for XSAT:IMS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:IMS has been successfully added to your 
